Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand
Bioorganic Chemistry · 2026-09 · 180 · 110207
DOI: 10.1016/j.bioorg.2026.110207 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026-09. Verfasst von Xiao Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engine…. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Prostatic Neoplasms, Antigens, Surface, Radiopharmaceuticals. Die Arbeit nennt 70 Literaturangaben.
Abstract (Originalsprache)
PSMA-617, the benchmark PSMA ligand widely used in targeted radionuclide therapy for prostate cancer (PCa), is limited by dose-dependent toxicity to key organs including the kidneys and salivary glands. In this study, a series of novel linker-modified compounds (P-1 to P-6) was rationally designed and synthesized to improve the therapeutic window. Using PSMA-617 as a positive control, systematic in vitro evaluations were performed for P-1 to P-6. All compounds exhibited strong hydrophilicity, good cellular internalization rates and plasma stability (half-life >48 h), but differed in enzyme inhibitory activity and cell-binding affinity. Compound P-6 exhibited in vitro activity comparable to that of PSMA-617, with a higher internalization (7.04% vs 5.17%) in LNCaP C42B cells, and therefore was selected for in vivo validation. In LNCaP PSMA-positive tumor-bearing mice, tumor uptake of 177Lu-P-6 was significantly higher than that of 177Lu-PSMA-617 at both 24 h post-injection (p.i.) (31.36 ± 7.42 vs 24.20 ± 3.20% ID/g) and 72 h p.i. (23.05 ± 5.15 vs 13.66 ± 4.50% ID/g). At 4 h p.i., renal exposure of 177Lu-P-6 was markedly lower than that of 177Lu-PSMA-617 (4.66% ID/g vs 6.90% ID/g). The tumor-to-kidney (T/K) ratios of 177Lu-P-6 at 4 h p.i. and 72 h p.i. were significantly higher than those of PSMA-617 (10.80 vs 8.10 and 51.29 vs 47.18, respectively). Moreover, accumulation in salivary glands and blood was lower for 177Lu-P-6. In conclusion, through linker optimization, 177Lu-P-6 achieves dual advantages of higher tumor retention and lower renal exposure while maintaining PSMA potency, demonstrating clear clinical translation potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Green Chemical Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Hubei Engineering Research Center for Advanced Fine Chemicals, School of Chemical…
- Mednovo Group Co., Ltd, Suzhou, Jiangsu 215163, China.
Zitieren
APA
Ji, X., Kong, X., Cai, C., Wang, Z., Zhang, H., & Long, S. (2026). Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand. Bioorganic Chemistry, 180, 110207. https://doi.org/10.1016/j.bioorg.2026.110207
Vancouver
Ji X, Kong X, Cai C, Wang Z, Zhang H, Long S. Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand. Bioorganic Chemistry. 2026;180:110207. doi:10.1016/j.bioorg.2026.110207
BibTeX
@article{Ji2026,
author = {Ji, Xiao and Kong, Xiangsheng and Cai, Chenchen and Wang, Zhiqian and Zhang, Hongzhang and Long, Sihui},
title = {Preparation, in vitro evaluation, and biodistribution study of a novel PSMA-targeted radioligand},
journal = {Bioorganic Chemistry},
year = {2026},
volume = {180},
pages = {110207},
doi = {10.1016/j.bioorg.2026.110207}
}
EUVIMED